Illumina, Inc. · ILMN · FY2026 Q3 · Calendar Q4 2026
Illumina raises FY2026 outlook as clinical sequencing demand holds up
The supplied analysis supports a constructive operating trajectory: clinical sequencing demand, NovaSeq X placements and raised FY2026 guidance offset weaker research consumables. The longer-term contribution from BioInsight and the Billion Cell Atlas remains less established, while pricing, China and supply-chain risks could temper execution.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about ILMN FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management again raised its outlook and reported continued clinical momentum. The discussion also advanced the data strategy, with the Billion Cell Atlas progressing and BioInsight incorporating AI models; research consumables remained a weaker area.
Guidance delta
Management raised FY2026 revenue guidance to $4.64-$4.66 billion and expects operating margin near the 23.6% high end.
Key takeaways
- Q3 revenue, margin and EPS exceeded guidance, according to the supplied analysis.
- NovaSeq X placements exceeded 80 units, supporting the consumables pipeline.
- Clinical sequencing consumables grew about 14% year over year, while research consumables declined modestly.
- Billion Cell Atlas and BioInsight are being developed as longer-term data and software growth initiatives.
Management priorities
- Expand the NovaSeq X installed base and convert placements into consumables demand
- Scale the Billion Cell Atlas and turn backlog into revenue
- Extend BioInsight with AI models and software offerings
- Continue the transition from legacy instruments to NovaSeq X
Follow ILMN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationIllumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +12.3% | Regeneron: Core Brands Grow as Pipeline Milestones Advance |
| DVA DaVita Inc. | FY2026 Q3 · Calendar Q4 2026 | +7.0% | -6.8% | DaVita’s expanded HD rollout and IKC progress support a narrowed outlook |
| SYK Stryker Corporation | FY2026 Q3 · Calendar Q4 2026 | -0.8% | -5.0% | Stryker cuts guidance as hip and knee demand slows |
| DXCM DexCom, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.1% | +5.6% | Dexcom raises 2026 outlook as G7 15-Day adoption expands |
| ALNY Alnylam Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +879.5% | -25.1% | Alnylam Q3: AMVUTTRA growth meets reimbursement uncertainty |
| KYMR Kymera Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | -4.8% | +0.1% | Kymera advances KT-621 and KT-579 while reaffirming runway |
Latest beats and misses
Who reports nextBeat on EPS
- STRKFY2026 Q3 · October 29, 2026+121.6% EPS-2.7% move
- RKTFY2026 Q3 · October 29, 2026+10.8% EPS+5.0% move
- STRCFY2026 Q3 · October 29, 2026+121.6% EPS-1.2% move
- WECFY2026 Q3 · October 29, 2026+21.5% EPS+3.7% move
- DVAFY2026 Q3 · October 29, 2026+7.0% EPS-6.8% move
- DXCMFY2026 Q3 · October 29, 2026+8.1% EPS+5.6% move
Missed on EPS
- SYKFY2026 Q3 · October 29, 2026-0.8% EPS-5.0% move
- DLR-PJFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLRFY2026 Q3 · October 29, 2026-8.4% EPS-3.0% move
- EGFY2026 Q3 · October 28, 2026-18.8% EPS+3.5% move
- MKLFY2026 Q3 · October 28, 2026-2.3% EPS+1.2% move
- KYMRFY2026 Q3 · October 29, 2026-4.8% EPS+0.1% move
Get the ILMN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T15:07:49.843208+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-30T15:30:46.212827+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-30T15:30:46.210088+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-30. For educational purposes only; not investment advice.